ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Potential for enfortumab vedotin plus pembrolizumab in cisplatin-ineligible loca...
Prof Jonathan E Rosenberg - Memorial Sloan Kettering Cancer Center, New York Cit...
Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first-li...
Dr Marcin Dzienis - Gold Coast University Hospital, Southport, Australia
From clinic to practice in NSCLC patients with exon 20 mutations
Prof Nicolas Girard - Institut Curie, Paris, France
ESMO 2022: Highlights, commentary and analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
Updates in prostate cancer from ESMO 2022
Prof Eleni Efstathiou, Prof Gerhardt Attard and Prof Boris Hadaschik
Latest in mRCC from ESMO 2022
Dr Javier Puente, Dr Bernard Escudier, Prof Viktor Grünwald and Prof Stéphane Ou...
Ideal duration of androgen deprivation therapy with post-operative radiotherapy ...
Prof Chris Parker - Institute of Cancer Research, Sutton, UK
Sotorasib shows superior PFS and ORR compared to docetaxel for NSCLC
Dr Silvia Novello - University of Turin, Turin, Italy
EGFR mutations in NSCLC - from biomarker to treatment selections in second line
Prof Nicolas Girard, Prof Keith Kerr, Dr Joshua Reuss and Dr Alfredo Addeo
Fruquintinib provides improvement in overall survival for refractory mCRC
Dr Nageshwara Arvind Dasari - MD Anderson Cancer Center, Houston, USA
ESMO 2022: Breast cancer highlights
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
Sotorasib demonstrates superior PFS vs docetaxel for previously treated non-smal...
Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA